Gilead Sciences, Inc.
Gilead Sciences, Inc. sells branded pharmaceutical therapies for HIV/AIDS, liver diseases, oncology, and cell therapy to healthcare providers, hospitals, and government agencies via direct sales teams, specialty distributors, and partnerships by discovering, developing, and commercializing innovative, patent-protected drugs that address serious health conditions and unmet medical needs.
LOCKED
Market: NormalKey Catalysts & Risks
Three items dominate the next 12 to 36 months. The first is the ramp of the twice-yearly HIV prevention injection, where management has guided to meaningful growth and highlighted broad payer coverage and new-to-prevention patients as positives; this is mainly upside because converting under-adherent prevention users expands the addressable market rather than only shifting existing prescriptions, but execution in primary care settings unused to injections is the key risk. The second is oncology: a US regulatory decision and potential launch for the Arcellx-derived multiple myeloma cell therapy, where full ownership and a differentiated safety profile are argued to support a larger commercial opportunity, and label expansion for the breast cancer antibody-drug conjugate into earlier lines, which would broaden the eligible patient population. Both are mainly upside but carry binary clinical and regulatory risk, and management has already absorbed a first-line trial miss on the conjugate, so readouts can cut either way. The third is policy, where US drug-pricing reform, tariffs and Medicaid funding remain unresolved; management argues its US-centric intellectual property and launch-phase portfolio give it relatively low exposure, but the direction of final rules leaves pricing and gross-to-net outcomes ambiguous over the medium term. Acquisition-related in-process research charges have pushed reported earnings into unusual territory in the near term, which can obscure underlying operating trends and create headline volatility even when cash economics are unchanged.
Two structural issues stand out. The first is pricing and access: Gilead's largest franchise sits directly in the path of US drug-pricing reform and international pressure on the list price of its new prevention medicine, and a United Nations programme publicly urged the company to cut that price, so if policy or political pressure forces materially lower realised pricing on a product expected to carry a large share of future growth, the economics of the pipeline replacement could be structurally weaker than the current franchise. The second is a compliance and legal history: the company settled a long-running kickback matter covering its HIV speaker programmes with extensive factual admissions, after years of patent litigation with the US government over prevention medicines; the direct cost was manageable, but the pattern shows regulatory and reputational friction around the core cash engine, which raises the cost of any future misstep. Company-specific concentration compounds this, because the HIV business still supplies most revenue and growth, so delays in replacement products or adverse policy on that franchise would hit the whole equity case rather than a single segment.
Research refreshed: 2nd of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | 529B | 74.04 | 3.40 | 8.6% |
| Amgen Inc. (AMGN) | 261B | 24.85 | 3.42 | 9.9% |
| AstraZeneca… (AZN) | 274B | 23.65 | 1.98 | 8.6% |
| Bristol-Mye… (BMY) | 159B | 13.47 | 2.47 | -0.2% |
| GSK plc (GSK) | 115B | 14.96 | 1.89 | 4.1% |
| Johnson & J… (JNJ) | 646B | 29.60 | 1.09 | 6.0% |
| Merck & Co.… (MRK) | 403B | 114.52 | 4.26 | 1.2% |
| Novartis AG (NVS) | 308B | 21.31 | 2.54 | 6.0% |
| Pfizer Inc. (PFE) | 221B | 36.73 | 3.89 | -1.6% |
| Sanofi (SNY) | 115B | 21.65 | 1.71 | 5.5% |
| Gilead Scie… (GILD) | 203B | N.M. | N.M. | 2.4% |
AI Opinion
Fundamentals
BUY: Q2 call evidence materially strengthens the recovery case and resolves much of the earlier uncertainty over acquisition-related losses. HIV sales grew 12% to $5.7B, Trodelvy grew 26% to $457M, and Livdelzi more than doubled to $167M; management raised FY2026 base-business growth guidance to 6%-7%. Yeztugo is already commercial, generating $232M quarterly sales, so launch execution rather than initial approval is the relevant catalyst. HIV concentration, price/channel effects and seasonal inventory build temper confidence in sustained organic growth.
Peer Comparison
Combined growth/quality ranking exceeds approximately 60% of quantified peers, indicating above-midpoint performance rather than leadership. Management's approximately 49% acquisition-adjusted operating margin strengthens the profitability assessment, but its top-quartile claim is not independently validated by supplied peer data. No defensible relative-valuation conclusion is available.
Macro Environment
Serious-condition therapies imply relatively resilient demand, but historical macro baselines do not establish current revenue causality. The most direct supplied macro-policy transmission is ACA-related slowing of U.S. HIV treatment growth; management assumes recovery to 2%-3% market growth. A 5.24% Treasury yield and weak short-term healthcare breadth are repricing headwinds, not evidence of deteriorating Gilead demand; international FX effects remain unquantified.
Key Metrics
TTM revenue growth 5.5%, Q2 revenue growth 10.2%, gross margin 79.59% and FCF margin 42.50% support business strength. Reported operating margin of -4.90% and ROIC of -3.66% reflect material accounting and capital-allocation burdens; adjusted profitability does not establish satisfactory acquisition returns. FY2026 HIV growth guidance is 9%-10%; trailing dividend yield is approximately 2.2%. Company valuation lacks peer or historical support and is not a basis for the recommendation.
Insider Activity
Slightly bearish but low-signal: approximately $85.37M of recorded annual sales and no buys, with only $0.87M sold in the latest 30 days. Small recent position reductions, 10b5-1 flags and derivative inflows substantially weaken the bearish interpretation; insider activity does not change the rating.
Income Statement
The earnings call identifies $11.2B of acquired IPR&D as the principal Q2 loss driver, materially reducing the significance of negative reported operating profitability as evidence of core deterioration. Management estimates approximately 49% operating margin excluding acquired IPR&D and illustrative FY2026 EPS of $8.50-$8.85, versus reported non-GAAP guidance of negative $0.65 to negative $0.30. These adjustments demonstrate underlying earning capacity but do not erase acquisition costs; cell therapy's expected mid-teens decline and ACA-related treatment softness remain operating headwinds.
Cash Flow
TTM operating cash flow of $13.6B and provider-defined FCF of $12.9B support reinvestment and deleveraging capacity. However, $12.1B of acquisitions plus $4.1B of dividends and $1.4B of repurchases exceeded that FCF, contributing to falling cash. Acquisition-related noncash charges explain much of the earnings/cash divergence, but durable cash conversion and disciplined post-acquisition spending still require confirmation.
Balance Sheet
Financial flexibility is weakened: cash of $3.2B, debt of $26.3B and net debt of $23.1B follow substantial acquisition spending; liabilities represent 76.2% of assets. Management's stated pause in additional sizable 2026 M&A supports stabilization, but debt maturities and acquisition returns remain unverified. Cash rebuilding and net-debt reduction are important confirmation signals.